What is ALS?
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that progressively destroys motor neurons in the brain, brainstem, and spinal cord, causing relentless muscle weakness that spreads throughout the body and typically results in death from respiratory failure within 2-5 years of onset 1.
Disease Characteristics
ALS manifests as progressive, painless muscle weakness that typically begins focally:
- 65% start with limb weakness (hand weakness or foot drop)
- 20-25% begin with cranial muscle involvement (speech/swallowing problems)
- 5-10% present with axial weakness (bent posture)
The disease spreads inexorably to other body regions, affecting both upper motor neurons (causing stiffness and spasticity) and lower motor neurons (causing weakness, fasciculations, atrophy, and flaccidity) 1.
Approximately 85% of cases are sporadic with no identifiable genetic or environmental cause, while 15% are familial 1. Over 60 genes have been linked to ALS, with C9orf72 mutations accounting for 40% of familial cases and SOD1 mutations for 20% 1.
Up to 50% of patients develop extra-motor manifestations including behavioral changes, executive dysfunction, and language problems, with 10-15% meeting criteria for frontotemporal dementia 2.
Can ALS Be Cured?
No, there is absolutely no cure for ALS 3, 1. This is unequivocal across all current guidelines and research. The disease remains universally fatal, and all available treatments only modestly slow progression without reversing or halting the disease 3.
How is ALS Treated?
Disease-Modifying Therapies
Three FDA-approved medications provide modest disease modification but do not cure or stop ALS progression:
- Riluzole (oral): Slows progression by 2-4 months 1
- Edaravone (oral): Slows progression by 2-4 months 1
- Tofersen (intrathecal): Gene therapy specifically for patients with SOD1 pathogenic variants, slows disease progression 1
These medications represent the only evidence-based pharmacologic interventions, though their benefit is limited 4.
Multidisciplinary Care (Most Important for Quality of Life and Survival)
Specialized multidisciplinary team care is associated with improved survival of 4-7 months and enhanced quality of life—comparable to or exceeding the benefit of available medications 1. This team should include:
- Neurologists
- Nurses
- Physical, occupational, and speech therapists
- Dietitians
- Social workers
- Respiratory therapists
Symptom Management and Supportive Care
The cornerstone of ALS treatment focuses on maintaining quality of life through:
Respiratory Support
- Non-invasive ventilation (NIV) for respiratory muscle weakness
- Mechanical ventilation decisions based on patient preferences
- Early respiratory monitoring is critical given the rapid progression 2, 5
Nutritional Support
- Gastrostomy tube placement when swallowing becomes unsafe
- Metabolic monitoring and nutritional optimization 5
Rehabilitation
- Physical therapy to maintain mobility and prevent complications
- Occupational therapy for adaptive equipment
- Speech therapy for communication strategies 5
Equipment and Services
A critical pitfall: Traditional reimbursement models create dangerous delays in equipment approval for ALS patients. Given the 2-5 year life expectancy and rapid progression, all equipment requests should be treated as urgent—delays can result in catastrophic safety risks rather than mere inconvenience 3.
Key Clinical Considerations
The 2024 NASEM guidelines emphasize that equitable access to affordable multidisciplinary care, services, and caregiver support is the immediate priority for improving both quantity and quality of life 3. The rapidly progressive nature of ALS does not fit traditional healthcare delivery models that assume slower timelines and potential for functional improvement 3.
Caregiver support is essential, as the burden of care is substantial and directly impacts patient quality of life 3.
While numerous experimental therapies are under investigation—including stem cell therapies, gene therapies, and novel neuroprotective agents—none have yet demonstrated sufficient efficacy to change the treatment paradigm 6, 7.